BackDesign Therapeutics Overview
Design Therapeutics Inc

Design Therapeutics Target Price

Analysts' average 12-month price target for Design Therapeutics is $21.

Get informed when a big investor buys or sells

+ Follow

Share Price

$14.33

Average Target Price

$20.5043.1% upside

2 analysts in the last 4 months

High: $21 | Low: $20

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-04Oppenheimer$2146.5% upsideOpen
2026-04-29Piper Sandler$2039.6% upsideOpen
2026-01-07Oppenheimer$1825.6% upsideOpen
2025-12-03Craig-HallumAdam Vogel$154.7% upsideOpen
2025-12-03Leerink PartnersJoseph Schwartz$142.3% downsideOpen
2024-05-07Piper SandlerYasmeen Rahimi$1216.3% downsideOpen
2023-08-15RBC CapitalLeonid Timashev$751.2% downsideOpen
2022-12-07Piper SandlerYasmeen Rahimi$42193.1% upsideOpen
2022-05-02RBC Capital$30109.4% upsideOpen
2022-01-19Goldman SachsMadhu Kumar$1030.2% downsideOpen

Design Therapeutics (DSGN) FAQ

As of the most recent data, DSGN shows a target price of $21. Scroll down for historical charts and peer comparison views.

If Design Therapeutics moved to the average analyst target of $21, shares would be roughly 43.1% higher than $14.33. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Design Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has Design Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $21) with ownership activity and broader fundamentals.

Design Therapeutics's target price is $21; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.